{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T06:22:22Z","timestamp":1785824542209,"version":"3.56.0"},"reference-count":11,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1097\/wnf.0b013e31816d91f9","type":"journal-article","created":{"date-parts":[[2008,10,30]],"date-time":"2008-10-30T07:10:03Z","timestamp":1225350603000},"page":"89-93","source":"Crossref","is-referenced-by-count":41,"title":["Open-Label Study Assessment of Safety and Adverse Effects of Subcutaneous Apomorphine Injections in Treating \"Off\" Episodes in Advanced Parkinson Disease"],"prefix":"10.1097","volume":"32","author":[{"given":"Peter A.","family":"LeWitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Ondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Van Lunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter B.","family":"Bottini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210203","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/mds.20279","article-title":"Impact of the motor complications of Parkinson's disease on the quality of life.","volume":"20","author":"Chapuis","year":"2005","journal-title":"Mov Disord"},{"key":"R2-7-20210203","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJM197603112941101","article-title":"Treatment of Parkinson's disease with aporphines. Possible role of growth hormone.","volume":"294","author":"Cotzias","year":"1976","journal-title":"N Engl J Med"},{"key":"R3-7-20210203","first-page":"251","article-title":"Apomorphine in Parkinson's disease.","volume":"56","author":"Schwab","year":"1951","journal-title":"Trans Am Neurol Assoc"},{"issue":"suppl 4","key":"R4-7-20210203","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1212\/WNL.62.6_suppl_4.S8","article-title":"Subcutaneously administered apomorphine: pharmacokinetics and metabolism.","volume":"62","author":"LeWitt","year":"2004","journal-title":"Neurology"},{"key":"R5-7-20210203","doi-asserted-by":"crossref","first-page":"816","DOI":"10.12968\/hosp.1999.60.11.1236","article-title":"Use of apomorphine in Parkinson's disease.","volume":"60","author":"O'Sullivan","year":"1999","journal-title":"Hosp Med"},{"key":"R6-7-20210203","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0303-8467(93)90128-4","article-title":"A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease.","volume":"95","author":"van Laar","year":"1993","journal-title":"Clin Neurol Neurosurg"},{"key":"R7-7-20210203","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1001\/archneur.58.9.1385","article-title":"A randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events.","volume":"58","author":"Dewey","year":"2001","journal-title":"Arch Neurol"},{"key":"R8-7-20210203","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.parkreldis.2006.06.012","article-title":"Continued efficacy and safety of subcutaneous apomorphine in patients with advanced Parkinson's disease.","volume":"13","author":"Pfeiffer","year":"2007","journal-title":"Parkinsonism Relat Disord"},{"key":"R10-7-20210203","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jns.2007.03.013","article-title":"APO303 Study Investigators. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.","volume":"258","author":"Pahwa","year":"2007","journal-title":"J Neurol Sci"},{"key":"R11-7-20210203","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality.","volume":"17","author":"Hoehn","year":"1967","journal-title":"Neurology"},{"key":"R13-7-20210203","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1365-2125.1980.tb04795.x","article-title":"Cross tolerance between two dopaminergic ergot derivatives-bromocriptine and lergotrile.","volume":"9","author":"Teychenne","year":"1980","journal-title":"Br J Clin Pharmacol"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00002826-200903000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,4]],"date-time":"2022-02-04T15:54:05Z","timestamp":1643990045000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-200903000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":11,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e31816d91f9","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}